Should You Be Worried After Bristol-Myers Squibb's Q3 Results?
It's been an up-and-down kind of year for Bristol-Myers Squibb (NYSE: BMY). Early in 2017, investors were concerned after the company opted not to pursue accelerated approval for a combination of Opdivo and Yervoy in first-line non-small cell lung cancer (NSCLC). Those worries largely evaporated, though, and BMS stock eventually went on to generate nice year-to-date gains.
Now, however, worries are resurfacing. Bristol-Myers Squibb announced its third-quarter results before the market opened on Thursday, with an immediate drop in its share price. Here are the highlights of those results -- and whether investors really need to be concerned this time around.
Image source: Getty Images.
Source: Fool.com
Bristol-Myers Squibb Aktie
Die Community zeigt leichtes Interesse an Bristol-Myers Squibb mit mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 65 € für Bristol-Myers Squibb impliziert eine deutliche Steigerung um über 20% gegenüber 43.94 €.